DN
Therapeutic Areas
Verrica Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| YCANTH (VP-102) | Molluscum Contagiosum | Approved |
| VP-103 | Plantar Warts | Pre-IND |
| VP-315 (LTX-315) | Basal Cell Carcinoma | Phase 2 |
| VP-315 | Squamous Cell Carcinomas | Pre-IND |
Leadership Team at Verrica Pharmaceuticals
JR
Jayson Rieger, Ph.D., M.B.A.
President & CEO
NR
Noah Rosenberg, M.D.
Chief Medical Officer
JK
John Kirby
Interim Chief Financial Officer
DZ
David Zawitz
Chief Operating Officer
CC
Chris Chapman
Chief Commercial Officer
PB
Paul B. Manning
Chairman of the Board
LE
Lawrence Eichenfield, M.D.
Director
MP
Mark Prygocki
Director
SS
Sean Stalfort
Director
GC
Gavin Corcoran, M.D.
Director